One shot to rule them all? new combo meningitis vaccine tested in teens
NCT ID NCT05087056
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing a new vaccine called MenABCWY that aims to protect against five types of meningococcal bacteria, which can cause serious infections like meningitis. Around 312 healthy teenagers will receive two doses of the vaccine on different schedules to see how safe it is and how well it triggers the immune system. The goal is to find a convenient way to protect against multiple strains with fewer shots.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- MenABCWY vaccine (combined meningococcal groups A, B, C, W, Y)
- What this could lead to
- If successful, this could lead to a single vaccine that protects against five major types of meningococcal disease, simplifying vaccination schedules for teens.
- What could go wrong
- This is a mid-stage trial with only 312 participants, so results may not apply to everyone. The vaccine may cause side effects like pain or fever, and it's not yet proven to prevent disease in the real world.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MENINGITIS, MENINGOCOCCAL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
GSK Investigational Site
Tucson, Arizona, 85745, United States
-
GSK Investigational Site
Ventura, California, 93003, United States
-
GSK Investigational Site
Macon, Georgia, 31210, United States
-
GSK Investigational Site
Valparaiso, Indiana, 84088, United States
-
GSK Investigational Site
Missoula, Montana, 80216, United States
-
GSK Investigational Site
Charlotte, North Carolina, 28226, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.